PDF(Pubmed)
Abstract：
The coronavirus disease 2019 (COVID-19) pandemic has caused changes in the global health system, causing significant setbacks in healthcare systems worldwide. This pandemic has also shown resilience, flexibility, and creativity in reacting to the tragedy. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection targets most of the respiratory tract, resulting in a severe sickness called acute respiratory distress syndrome that may be fatal in some individuals. Although the lung is the primary organ targeted by COVID-19 viruses, the clinical aspect of the disease is varied and ranges from asymptomatic to respiratory failure. However, due to an unorganized immune response and several affected mechanisms, the liver may also experience liver cell injury, ischemic liver dysfunction, and drug-induced liver injury, which can result in respiratory failure because of the immune system\'s disordered response and other compromised processes that can end in multisystem organ failure. Patients with liver cirrhosis or those who have impaired immune systems may be more likely than other groups to experience worse results from the SARS-CoV-2 infection. We thus intend to examine the pathogenesis, current therapy, and consequences of liver damage concerning COVID-19.
摘要：
2019年冠状病毒病（COVID-19）大流行引起了全球卫生系统的变化，在全球医疗保健系统中造成重大挫折。这场大流行也表现出了韧性，灵活性,以及对悲剧做出反应的创造力。严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）感染的目标是大部分呼吸道，导致一种称为急性呼吸窘迫综合征的严重疾病，对某些人来说可能是致命的。尽管肺是COVID-19病毒靶向的主要器官，该疾病的临床方面各不相同，从无症状到呼吸衰竭不等。然而,由于无组织的免疫反应和几种受影响的机制，肝脏也可能经历肝细胞损伤，缺血性肝功能障碍，和药物性肝损伤，这可能会导致呼吸衰竭，因为免疫系统的紊乱反应和其他受损的过程，可以结束多系统器官衰竭。肝硬化患者或免疫系统受损的患者可能比其他人群更有可能经历SARS-CoV-2感染的更糟糕的结果。因此，我们打算检查发病机理，目前的治疗，以及与COVID-19有关的肝损伤的后果。
